The TSANZ and Lung Foundation Australia 2023 landscape survey of lung cancer care across Australia and Aotearoa New Zealand

被引:1
作者
Nash, Jessica [1 ,2 ]
Leong, Tracy [3 ,4 ]
Dawkins, Paul [5 ,6 ]
Stone, Emily [7 ,8 ]
Marshall, Henry [9 ,10 ]
Brims, Fraser [1 ,2 ,11 ]
机构
[1] Curtin Univ, Curtin Med Sch, Perth, WA, Australia
[2] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA, Australia
[3] Austin Hlth, Dept Resp & Sleep Med, Melbourne, Vic, Australia
[4] Univ Melbourne, Melbourne, Vic, Australia
[5] Middlemore Hosp, Auckland, New Zealand
[6] Univ Auckland, Fac Med & Hlth Sci, Auckland, New Zealand
[7] St Vincents Hosp, Dept Thorac Med & Lung Transplantat, Sydney, NSW, Australia
[8] UNSW, Sch Clin Med, Sydney, NSW, Australia
[9] Prince Charles Hosp, Dept Thorac Med, Brisbane, Qld, Australia
[10] Univ Queensland, Thorac Res Ctr, Brisbane, Qld, Australia
[11] Inst Resp Hlth, Perth, WA, Australia
关键词
Australia; healthcare services; infrastructure; lung cancer; New Zealand;
D O I
10.1111/resp.14693
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background and Objective: Unwarranted variations in lung cancer care have been well described in both Australia and Aotearoa New Zealand, with shortfalls in hospital-based workforce and infrastructure previously demonstrated. A survey of lung cancer clinicians was performed to gain an updated understanding of current workforce and infrastructure. Methods: An online Qualtrics survey included questions on institutional demographics, estimated lung cancer case load, multidisciplinary team (MDT) characteristics including workforce and local infrastructure. We sought to obtain one response from every institution treating lung cancer in Australia and Aotearoa New Zealand. Results: Responses were received from 89 institutions, estimated to include 85% centres treating lung cancer in Australia and 100% of public hospitals in Aotearoa New Zealand. Lung cancer nurse specialist and Nuclear Medicine are poorly represented in multidisciplinary teams (MDTs) with just 34/88 (38%) institutions fulfilling recommended core workforce for MDT meetings. Case presentation is low with 32/88 (36%) regularly discussing all lung cancer patients at MDT. Metropolitan institutions appear to have a more comprehensive range of services on site, compared to non-metropolitan institutions. Few (4/88) institutions have embedded smoking cessation services. Compared to the previous 2021 Landscape Survey, thoracic surgery representation and core MDT workforce have improved, with modest change in specialist nurse numbers. Conclusion: This wide-reaching survey has identified persistent deficiencies and variations in lung cancer workforce and gaps in infrastructure. Multidisciplinary collaboration and care coordination are needed to ensure all patients can access timely and equitable lung cancer care. image
引用
收藏
页码:405 / 412
页数:8
相关论文
共 35 条
  • [31] Country of birth and non-small cell lung cancer incidence, treatment, and outcomes in New South Wales, Australia: a population-based linkage study
    Alana Little
    David Roder
    George W. Zhao
    Sheetal Challam
    Ashanya Malalasekera
    David Currow
    BMC Pulmonary Medicine, 22
  • [32] Country of birth and non-small cell lung cancer incidence, treatment, and outcomes in New South Wales, Australia: a population-based linkage study
    Little, Alana
    Roder, David
    Zhao, George W.
    Challam, Sheetal
    Malalasekera, Ashanya
    Currow, David
    BMC PULMONARY MEDICINE, 2022, 22 (01) : 366
  • [33] Lung cancer treatment and mortality for Aboriginal people in New South Wales, Australia: results from a population-based record linkage study and medical record audit
    Alison Gibberd
    Rajah Supramaniam
    Anthony Dillon
    Bruce K. Armstrong
    Dianne L. O’Connell
    BMC Cancer, 16
  • [34] Lung cancer treatment and mortality for Aboriginal people in New South Wales, Australia: results from a population-based record linkage study and medical record audit
    Gibberd, Alison
    Supramaniam, Rajah
    Dillon, Anthony
    Armstrong, Bruce K.
    O'Connell, Dianne L.
    BMC CANCER, 2016, 16
  • [35] Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation-Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy
    Aye, Phyu Sin
    Barnes, Joanne
    Laking, George
    Cameron, Laird
    Anderson, Malcolm
    Luey, Brendan
    Delany, Stephen
    Harris, Dean
    McLaren, Blair
    Brenman, Elliott
    Wong, Jayden
    Lawrenson, Ross
    Arendse, Michael
    Tin, Sandar Tin
    Elwood, Mark
    Hope, Philip
    McKeage, Mark James
    JMIR RESEARCH PROTOCOLS, 2024, 13